Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy
Status:
NOT_YET_RECRUITING
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 open-label extension (OLE) study to evaluate the long-term safety, tolerability, efficacy, pharmacokinetics, and the pharmacodynamics (PD) through potential exploratory biomarker(s) of intravenous (IV) WVE-N531 in patients with DMD who participated in another study of WVE-N531. All patients will have rolled over from a previous study of WVE-N531.